K. Dinnon

Protective efficacy of rhesus adenovirus COVID-19 vaccines against mouse-adapted SARS-CoV-2

This study evaluates the protective efficacy of rhesus adenovirus serotype 52 vaccines against a mouse-adapted SARS-CoV-2 strain, showing robust antibody responses and protection against viral replication and disease.

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2

This study designs SARS-CoV-2 nanoparticle vaccines that induce strong neutralizing antibodies in mice, with higher titers and lower doses than existing trimer vaccines.

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate

This paper describes NDV vector vaccines expressing SARS-CoV-2 spike protein that protect mice from viral challenge and can be produced cost-effectively in chicken eggs.

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus

This study demonstrates that the antiviral NHC/EIDD-2801 inhibits SARS-CoV-2 and multiple coronaviruses, showing therapeutic efficacy and oral bioavailability in mice.

Trypsin treatment unlocks barrier for zoonotic coronaviruses infection

This study shows that proteolytic cleavage, not receptor binding, is the main barrier for two MERS-like bat coronaviruses to infect human cells, and that trypsin treatment can overcome this barrier.

Combination attenuation offers strategy for live-attenuated coronavirus vaccines

This study shows combining NSP16 mutation with other attenuating mutations creates a safe and effective live-attenuated coronavirus vaccine that works in aged mice and against heterologous challenges.